Enhanced recovery after surgery in children undergoing abdominal surgery: meta-analysis

Bte Azahari Hidayah^{1,2,3}, Zheng An Toh^{1,2,3} (), Ling Jie Cheng^{3,4} (), Bin Daud Syahzarin^{1,2,3}, Yi Zhu⁵, Tarja Pölkki^{6,7}, Honggu He^{3,*} () and Vidyadhar Padmakar Mali⁸ ()

¹Alice Lee Centre for Nursing Studies, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore

²Division of Nursing, National University Hospital, Singapore

³National University Health System, Singapore

⁴Saw Swee Hock School of Public Health, National University of Singapore, Singapore

⁵Department of Musculoskeletal Pain Rehabilitation, The Fifth Affiliated Hospital of Zhengzhou University, Zhengzhou, China

⁶Research Unit of Nursing Science and Health Management, University of Oulu, Oulu, Finland

⁷Department of Children and Women, Oulu University Hospital, Oulu, Finland

⁸Department of Paediatric Surgery, National University Hospital, Singapore

*Correspondence to: Honggu He, Alice Lee Centre for Nursing Studies, Yong Loo Lin School of Medicine, National University of Singapore, Level 2, Clinical Research Centre, Bock MD11, 10 Medical Drive, Singapore 117597, Singapore (e-mail: nurhhg@nus.edu.sg)

Abstract

Background: Enhanced recovery after surgery (ERAS) is a multimodal approach that streamlines patient processes before, during, and after surgery. The goal is to reduce surgical stress responses and improve outcomes; however, the impact of ERAS programmes in paediatric abdominal surgery remains unclear. The authors aimed to review the effectiveness of ERAS on clinical outcomes in children undergoing abdominal surgery.

Method: CINAHL, CENTRAL, Embase, ProQuest, PubMed, and Scopus were searched for relevant studies published from inception until January 2021. The length of hospital stay (LOS), time to oral intake, time to stool, complication rates, and 30-day readmissions were measured. Meta-analyses and subgroup analyses were conducted using RevMan 5.4 with a random-effects model.

Results: Among 2371 records from the initial search, 111 articles were retrieved for full-text screening and 12 were included for analyses. The pooled mean difference (MD) demonstrated reduced LOS (MD -1.96; 95 per cent c.i. -2.75 to -1.17), time to oral intake (MD -3.37; 95 per cent c.i. -4.84 to -1.89), and time to stool (MD -4.19; 95 per cent c.i. -6.37 to -2.02). ERAS reduced postoperative complications by half and 30-day readmission by 36 per cent. Subgroup analyses for continuous outcomes suggested that ERAS was more effective in children than adolescents.

Conclusion: ERAS was effective in improving clinical outcomes for paediatric patients undergoing abdominal surgery.

Introduction

Nearly half of paediatric inpatient operations performed are abdominal¹; however, no single measure has been found to reduce morbidity and hospital stay. Enhanced recovery after surgery (ERAS) was introduced by Kehlet² (1997) as a multimodal perioperative care pathway that streamlines patient processes before, during, and after surgery³, by preventing surgical stress and endocrine-metabolic reponses². ERAS has since been developed and implemented in various surgical specialties⁴, but rarely in the paediatric population, possibly due to the physiological differences between children and adults. Some of the interventions might be deemed inappropriate or more challenging to implement in paediatric populations⁵. Most current studies employ different combinations of ERAS principles, and the best practices for applying adult ERAS principles to children have yet to be determined⁵. There are no current recommendations regarding the modification of ERAS principles for paediatric populations⁵. Non-adherence to the ERAS protocols is associated with an increased rate of medical errors and adverse events 6,7 .

In adults, ERAS protocols reduce the length of hospital stay (LOS), postoperative complications, time of return to gastrointestinal function, and total cost of hospital stay⁸. In children, Shinnick et al.⁹ could not demonstrate a reduction in hospital stay as a result of ERAS, which was possibly due to the increased use of minimally invasive surgery. A meta-analysis of ERAS protocols in paediatric populations undergoing gastrointestinal surgery found no significant difference in the incidence of complications or 30-day readmission¹⁰; however, it decreases the LOS, improves the recovery of gastrointestinal function, and reduces the need for perioperative infusion, postoperative opioid administration, and costs. The review was limited by using only three databases and there were insufficient trials to determine whether there was significant heterogeneity among the studies or publication bias. Funnel plot asymmetry tests should only be conducted if the meta-analysis includes at least 10 studies¹¹. To address this issue,

© The Author(s) 2023. Published by Oxford University Press on behalf of BJS Society Ltd.

This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/ licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com

Received: August 25, 2022. Revised: October 13, 2022. Accepted: October 13, 2022

the authors aimed to synthesize the available evidence of the effectiveness of ERAS in reducing the LOS, time to oral intake, time to stool, rates of complications, and 30-day readmissions in children undergoing abdominal surgery, comparing it with traditional outcomes.

Methods

This systematic review followed the PRISMA guidelines¹². The review protocol, which was strictly followed in this review, was submitted to the author's institution before the commencement of database searches but was not registered.

Eligibility criteria

Patients aged between 4 weeks and 18 years who underwent abdominal surgery with the implementation of at least three elements of ERAS distinctive from traditional care were included (Table 1). Abdominal surgery refers to the surgical procedures performed to diagnose or treat a medical condition in the abdomen, including the stomach, small intestine, spleen, appendix, colon, and rectum. Studies that included a mixture of operations or a mixture in the population were included if the participants were within the age range, and data for those undergoing abdominal surgery could be analysed separately. Studies comparing ERAS with traditional perioperative care were included. The primary outcome was the LOS, and the secondary outcomes were time to oral intake, time to stool, rates of postoperative complications, and 30-day readmission. Studies adopting all English-language quantitative study designs (for example RCTs, quasi-experimental designs, cohort studies, or case-control studies) were included. Studies with ERAS compared with another intervention or used as a co-intervention were excluded. Conference abstracts, editorials, and letters were excluded. No time limit was applied.

Information sources, search strategy, and selection process

The PubMed Clinical Queries, Cochrane Database of Systematic Reviews (SRs), and PROSPERO databases were searched to prevent duplication of SRs. Following consultation with the library team, an extensive three-step search strategy was developed based on the Cochrane Handbook for Systematic Review. The authors searched published and unpublished studies through six databases, including PubMed, CENTRAL, Embase, CINAHL, Scopus, and ProQuest Dissertations and Theses Global. Based on different syntax rules of each database, index and key terms were explored and truncated (Table S1). Ongoing and unpublished trials were searched via a clinical trial registry (ClinicalTrials.gov). Hand-searching was performed in related articles and similar articles of relevant databases and the reference lists of selected studies and relevant SRs. All searches were conducted from inception until January 2021. Two independent reviewers (H.B.A. and S.B.D.) undertook screening and extraction of selected studies as well as the quality appraisal. Disagreements were resolved by the discussion with a third reviewer (H.G.H.).

Data extraction, methodological quality appraisal, and data analysis

Data extracted included authors, year, setting, country, design, sample size, intervention, outcomes, measures, attrition rate, intention-to-treat, protocol, trial registration, ERAS elements used, and funding. In the event of missing or incomplete data, authors were contacted for more information; if there was no response from the author, the study was excluded from the meta-analysis for the particular outcome. The studies were appraised using the Joanna Briggs Institute (JBI) critical appraisal instrument for RCTs¹³ and cohort studies¹⁴. RevMan 5.4 Software was used for meta-analyses. Dichotomous data were analysed using the Mantel–Haenszel (M–H) method, calculating the risk ratio (RR) with a 95 per cent confidence interval (c.i.). Continuous data were analysed using the inverse variance (IV) method, calculating the mean(s.d.). Studies measuring the same outcome with a different measurement were combined using standardized mean difference (MD). Z-statistics was used to evaluate the overall combined effect of the intervention. Effect size, measuring the magnitude of ERAS effect, was expressed as Cohen *d* where d(0.1) = very small, d(0.2) = small, d(0.5) = medium, d (0.8) = large, d (1.2) = very large, and d (2.0) = huge (Sawilwsky, 2009). I² statistics were used to assess heterogeneity. When

Table 1 Enhanced recovery after surgery protocol parameters

Phases of surgery	Key aspects	ERAS protocol for paediatrics
Preoperative	Preoperative counselling	Included
-	Preoperative bowel preparation	Antibiotic and mechanical
	Nutritional assessment and treatment	Included
	Preoperative fasting (oral)	Fasting from breast milk for 4 h, formula for 6 h. Drinking 10% glucose solution
	Use of sedative preanaesthetic	Included with internal anaesthesia/surgical consensus
	Preoperative antibiotics	Within 60 min before incision
Intraoperative	Anaesthesia	Combination of caudal and general anaesthesia, opioid-sparing, or opioid-free
-	Surgery	Minimally invasive surgery is preferred
	Intraoperative fluid management	Included with internal anaesthesia/surgical consensus
	Maintenance of normothermia	Included
	Abdominal drainage tubes	Omitted (unless excessive exudates)
Postoperative	Nasogastric tube	Included (but removed as soon as possible)
-	Urethral catheters	Early removal POD 1–2
	Nausea and vomiting prophylaxis treatment	Included
	Early removal of i.v. fluids	Included
	Postoperative fasting	Early feeding
	Routine postoperative mobilization care	Mobilization on POD 1
	Pain assessment and analgesia	Included (scheduled opioid-free analgesia)

ERAS, enhanced recovery after surgery; i.v. intravenous; POD, postoperative day.

а									
		ERAS	3	Cor	trol		MD		MD
Study or subgroup	Mea	an s.d	. Total N	lean s	s.d. Total	Weight	(%) IV, random, 95%	őc.i. Ⅳ, ra	ndom, 95% c.i.
Edney et al.20	2.	.67 0.7	4 36	4.67 2	2.96 36	8.8	-0.92 (-1.40, -	0.43)	*
Fattah et al.21	1.	.93 2.2	23 30	4.23 2	2.21 30	8.7	-1.02 (-1.56, -	0.48)	
Haid et al 23	4.	.01 U.2 93 D.6	0 00 4 15	19.87 2	0.20 57	67	-10.74 (-12.14, -	3 55)	
Modrzyk et al 24	6	08 2	6 13	8 64	24 14	83	_0.99 (_1.80 _	0.19)	
Phillins et al 25	15	58 84	7 28 3	235.8 19	2.4 14	87	-0.53 (-1.00, -	0.02)	-
Purcell et al.26	114	.47 67.4	8 98 1	57.27 7	4.3 41	8.9	-0.61 (-0.98, -	0.24)	-
Rove et al.27	:	5.7 5	.1 13	8	7.3 26	8.5	-0.34 (-1.01,	0.33)	
Short et al.28		3 1.4	8 36	4 1	.48 43	8.8	-0.67 (-1.12, -	0.21)	-
Tan et al.29	:	5.3 0	.6 15	9.1	2.5 18	8.2	–1.96 (–2.81, –	1.11)	
Tlacuilo-Parra et al.30		13	5 30	72	40 30	8.6	-2.04 (-2.67, -	1.41)	
Yalcin et al.31	1.	.92 0.6	61 61	2.54 0	0.66 51	8.9	–0.95 (–1.34, –	0.56)	*
Total (95% c i)			113		384	100.0	_1 96 (_2 75 _	1 17)	
Hotorogonoity: $r^2 = 1^{-1}$	702 _ 2	240 44 1	1 d f D z	0 00001	· 12 _ 0.59/	100.0	-1.30 (-2.73, -	····/)	►
Test for overall effect:	7 = 1 87	P > 0.00	1 u.i., r <	0.00001	, 1 = 95%			-10 -5	0 5 10
rescior overall effect.	2 = 4.07	, / < 0.00	001					Favours ER/	AS Favours control
b									
	E	RAS		Control			MD		
Study or subgroup	Mean	s.d. To	tal Mean	s.d.	Total We	aight (%)	IV. random. 95% c.i.	IV. ra	ndom. 95% c.i.
Eattab et al 21	1 23	0.68.3	0 20	1 / 5	30	15.1	_1 /6 (_2 03 _0 8	R)	•
Gao et al 22	8.07	0.00 0	8 30 75	1.45	57	07 _	-1.40 (-2.05, -0.0	5) 1) —	
Modrzyk et al 24	3.23	18 1	3 61/	2 1.30	1/	14.7	-1 /8 (-2 35 -0 6	*/ 1)	-
Phillips et al 25	30	25 2	8 65 5	486	23	15.2	_0.70 (_1.27 _0.1	3)	-
Purcell et al 26	24.5	22 8 9	8 470	40.6	41	15.3	-0.80 (-1 18 -0 4	2)	-
Short et al 28	0.67	074 3	6 7	1 48	13	15.3	-1 10 (-1 57 -0.4	-/ 2)	-
Tan et al 29	4.4	0.5 1	5 77	2 2	18	14 7	-2.18 (-3.07 -1.2	-,))	+
. an ot a.		0.0 1	S 1.1	2	10		2.10 (0.07, -1.0	~,	
Total (95% c.i.)		28	8		226	100.0	-3.37 (-4.84, -1.89	9)	•
Heterogeneity: $\tau^2 = 3.6$	65: $\gamma^2 = 2$	227.60.6	d.f., P < 0	.00001:	l ² = 97%			í <u> </u>	
Test for overall effect:	Z = 4.48	, P < 0.00	0001	,				-20 -10	0 10 20
								Favours ERAS	Favours control
С									
<u> </u>	F	RAS		Control			MD		MD
Study or subgroup	Mean	sd To	tal Mean	s d	Total We	aiaht (%)	IV random 95% ci	IV rai	ndom 95% ci
Ednov of al 20	14.07.1	0.67 2	6 20 02	22.50	26	17.5	101/150.05	יין אין אין אין אין אין אין אין אין אין	•
Eattah et al 21	14.07	0.86 3	0 30.03	1 02	30	17.5	-0.42 (-0.93, 0.0	2)	
Gao et al.22	17.18	0.94 6	8 44.39	1.82	57	14.4 -	19.17 (-21.6116.7)	3) —	-
Haid et al.23	11.93	0.64 1	5 19.87	2.04	15	16.2	-5.11 (-6.67, -3.5	5)	
Modrzyk et al.24	2.23	0.9 1	3 3.5	1.9	14	17.2	-0.82 (-1.61, -0.03	3)	-
Rove et al.27	2	1.66 1	3 4	1.57	26	17.3	–1.22 (–1.95, –0.50	D)	+
Total (95% c.i.)		17	5		178 *	100.0	-4.19 (-6.37, -2.0	2)	
Heterogeneity: $\tau^2 = 6.9$	98; $\chi^2 = 2$	242.83, 5	d.f., P < 0	.00001;	$l^2 = 98\%$			-20 -10	0 10 20
lest for overall effect:	Z = 3.78	, <i>P</i> < 0.00	002					Favours ERAS	Favours control
Ч									
u				4					
Study or subgroup	Evente	Total	Evente	Total	Weight	(%) M_H	RISK ratio	Kisk fa M-H random	1110 95% ci
Ednov of al 20	2	26	Events 5	26	10.4	(70) MI-II) 40 (0 09 1 02)		-
Eulley et al.	2	20	0	30	24.0		5.40(0.00, 1.93)		
	4	50	2	50	21.0		1.30 (0.17, 1.40)		
Haid of al ²³	4	16	3 E	37	12.2		1.12 (0.20, 4.79)		
Short of al 28	I F	10	0	10	5.0 7 חכ) 80 (0.31 2.02)		_
Tan et al 29	0	15	3	10	23.1		13 (0.01, 2.02)		_
Tloquilo Porro et cl.30	4	15	4	10	3.2). 13 (U.U.I, Z.Z/)		
Valcin et al 31	ו ס	50	2	50	4./		10 (0.00, 0.22)		
raion et al.	2	01	5	51	11.7	(
Total (95% c i)		291		280	100.0	ſ).50 (0.30, 0.83)	▲	
Total events	20	201	15	200	100.0	,		•	
Hotorogonoity: $r^2 = 0.0$	20 10·2 – 5	60 7 d	40 P_06	o. 12 _ ∩0	/				<u>L</u>
Test for overall effect:	Z = 2.68	P = 0.00)7	5,7 = 07	0		0.001	0.1 1	10 1000
	L = L .00,	, , = 0.00						Favours ERAS	Favours control
•									
е									
<u>e</u>	ER	AS	Con	trol			Risk ratio	Risk ra	atio
C Study or subgroup	ER Events	AS Total	Con Events	trol Total	Weight	(%) M-H	Risk ratio , random, 95% c.i.	Risk r M-H, random	atio I, 95% c.i.
Edney et al. ²⁰	ER Events	AS Total 36	Con Events	trol Total 36	Weight 4.6	(%) M-H	Risk ratio I, random, 95% c.i. 0.10 (0.01, 0.74)	Risk ra M-H, random	ntio 1, 95% c.i.
Edney et al. ²⁰ Fattah et al. ²¹	ER Events	Total 36 30	Con Events 10 1	trol Total 36 30	Weight 4.6 1.8	(%) M-H	Risk ratio I, random, 95% c.i. 0.10 (0.01, 0.74)	Risk ra M-H, random	atio 1, 95% c.i.
E Study or subgroup Edney et al. ²⁰ Fattah et al. ²¹ Phillips et al. ²⁵	ER Events 1 0 4	2AS Total 36 30 23	Con Events 10 1 5	trol Total 36 30 28	Weight 4.6 1.8 12.9	<mark>(%) M-H</mark> ((Risk ratio I, random, 95% c.i. 0.10 (0.01, 0.74) 0.33 (0.01, 7.87) 0.97 (0.30, 3.21)	Risk ra M-H, random	ntio , 95% c.i.
Study or subgroup Edney <i>et al.</i> ²⁰ Fattah <i>et al.</i> ²¹ Phillips <i>et al.</i> ²⁵ Purcell <i>et al.</i> ²⁶	ER Events 1 0 4 18	2AS Total 36 30 23 98	Con Events 10 1 5 9	trol Total 36 30 28 41	Weight 4.6 1.8 12.9 36.2	(%) M-H (((Risk ratio I, random, 95% c.i. 0.10 (0.01, 0.74) 0.33 (0.01, 7.87) 0.97 (0.30, 3.21) 0.84 (0.41, 1.71)	Risk ra M-H, randon	itio , 95% c.i
E Study or subgroup Edney et al. ²⁰ Fattah et al. ²¹ Phillips et al. ²⁵ Purcell et al. ²⁶ Rove et al. ²⁷	Events 1 0 4 18 1 1	2AS Total 36 30 23 98 13	Con Events 10 1 5 9 7	trol Total 36 30 28 41 26	Weight 4.6 1.8 12.9 36.2 4.7	(%) M-H (((((Risk ratio I, random, 95% c.i. 0.10 (0.01, 0.74) 0.33 (0.01, 7.87) 0.97 (0.30, 3.21) 0.84 (0.41, 1.71) 0.29 (0.04, 2.08)	Risk ra M-H, randon	ntio 1, 95% c.i
E Study or subgroup Edney et al. ²⁰ Fattah et al. ²¹ Phillips et al. ²⁵ Purcell et al. ²⁶ Rove et al. ²⁷ Short et al. ²⁸	Events 1 0 4 18 1 4 1 4 1 4 1 4 1 4 1 4 1 4 1 4 1	Total 36 30 23 98 13 36	Con Events 10 1 5 9 7 10	trol Total 36 30 28 41 26 43	Weight 4.6 1.8 12.9 36.2 4.7 16.0	(<mark>%) M-H</mark> ((((((Risk ratio I, random, 95% c.i. 0.10 (0.01, 0.74) 0.33 (0.01, 7.87) 0.97 (0.30, 3.21) 0.84 (0.41, 1.71) 0.29 (0.04, 2.08) 0.48 (0.16, 1.40)	Risk random	ntio , 95% c.i.
E Study or subgroup Edney et al. ²⁰ Fattah et al. ²¹ Phillips et al. ²⁵ Purcell et al. ²⁸ Rove et al. ²⁷ Short et al. ²⁸ Tan et al. ²⁹	Events 1 0 4 18 1 4 0 0	Total 36 30 23 98 13 36 15	<u>Con</u> Events 10 1 5 9 7 10 0	trol Total 36 30 28 41 26 43 18	Weight 4.6 1.8 12.9 36.2 4.7 16.0	(%) M-H ((((((((((Risk ratio I, random, 95% c.i. 0.10 (0.01, 0.74) 0.33 (0.01, 7.87) 0.97 (0.30, 3.21) 0.84 (0.41, 1.71) 0.29 (0.04, 2.08) 0.48 (0.16, 1.40) Not estimable	Risk radom	ntio , 95% c.i
E Study or subgroup Edney et al. ²⁰ Fattah et al. ²¹ Phillips et al. ²⁵ Purcell et al. ²⁶ Rove et al. ²⁷ Short et al. ²⁸ Tan et al. ²⁹ Yalcin et et al. ³¹	ER Events 1 0 4 18 1 4 0 8	Total 36 30 23 98 13 36 15 61	Con Events 10 1 5 9 7 10 0 9	trol Total 36 30 28 41 26 43 18 51	Weight 4.6 1.8 12.9 36.2 4.7 16.0 23.9	(%) M-H (((((((((((((((((((Risk ratio , random, 95% c.i. 0.10 (0.01, 0.74)	Risk random	ntio , 95% c.i
E Study or subgroup Edney et al. ²⁰ Fattah et al. ²¹ Phillips et al. ²⁵ Purcell et al. ²⁶ Rove et al. ²⁷ Short et al. ²⁸ Tan et al. ²⁹ Yalcin et al. ³¹	Erents	Total 36 30 23 98 13 36 15 61	Con Events 10 1 5 9 7 10 0 9	trol Total 36 30 28 41 26 43 18 51	Weight 4.6 1.8 12.9 36.2 4.7 16.0 23.9	(%) M-H ((((((((((Risk ratio 1, random, 95% c.i. 0.10 (0.01, 0.74) 0.33 (0.01, 7.87) 0.97 (0.30, 3.21) 0.84 (0.41, 1.71) 0.29 (0.04, 2.08) 0.48 (0.16, 1.40) Not estimable 0.74 (0.31, 1.79)	Risk r. M-H, random	ntio , 95% c.i.
E Study or subgroup Edney et al. ²⁰ Fattah et al. ²¹ Phillips et al. ²⁵ Purcell et al. ²⁵ Rove et al. ²⁷ Short et al. ²⁸ Tan et al. ²⁹ Yalcin et al. ³¹	Events 1 0 4 18 1 4 0 8	AS Total 36 30 23 98 13 36 15 61 312	Con Events 10 1 5 9 7 10 0 9 9	trol Total 36 30 28 41 26 43 18 51	Weight (4.6 1.8 12.9 36.2 4.7 16.0 23.9	(%) M-H	Risk ratio 1, random, 95% c.i. 0.10 (0.01, 0.74) 0.33 (0.01, 7.87) 0.397 (0.30, 3.21) 0.44 (0.41, 1.71) 0.29 (0.04, 2.08) 0.48 (0.16, 1.40) Not estimable 0.74 (0.31, 1.79) 0.64 (0.42, 0.90)	Risk random	ntio , 95% c.i.
E Study or subgroup Edney et al. ²⁰ Fattah et al. ²¹ Phillips et al. ²⁵ Purcell et al. ²⁶ Rove et al. ²⁷ Short et al. ²⁸ Tan et al. ²⁹ Yalcin et al. ³¹ Total (95% c.i.)	ER Events 1 0 4 18 1 4 0 8	AS Total 36 30 23 98 13 36 15 61 312	Com Events 10 1 5 9 7 10 0 9	trol Total 36 30 28 41 26 43 18 51 273	Weight 4.6 1.8 12.9 36.2 4.7 16.0 23.9 100.0	(%) M-H (((((((((((((((((((Risk ratio 1, random, 95% c.i. 0.10 (0.01, 0.74) 0.33 (0.01, 7.87) 0.97 (0.30, 3.21) 0.84 (0.41, 1.71) 0.29 (0.04, 2.08) 0.48 (0.16, 1.40) Not estimable 0.74 (0.31, 1.79) 0.64 (0.42, 0.99)	Risk r. M-H, randon	atio , 95% c.i
e Study or subgroup Edney et al. ²⁰ Fattah et al. ²¹ Phillips et al. ²⁵ Purcell et al. ²⁶ Rove et al. ²⁷ Short et al. ²⁸ Tan et al. ²⁹ Yalcin et al. ³¹ Total (95% c.i.) Total events	ER Events 1 0 4 18 1 4 0 8 36	Total 36 30 23 98 13 36 15 61 312	Con Events 10 1 5 9 7 10 0 9 51	trol Total 36 30 28 41 26 43 18 51 273	Weight 4.6 1.8 12.9 36.2 4.7 16.0 23.9 100.0	(%) M-H (((((((((((((((((((Risk ratio 1, random, 95% c.i. 0.10 (0.01, 0.74) 0.33 (0.01, 7.87) 0.37 (0.30, 3.21) 0.84 (0.41, 1.71) 0.29 (0.04, 2.08) 0.48 (0.16, 1.40) Not estimable 0.74 (0.31, 1.79) 0.64 (0.42, 0.99)	Risk random	ntio , 95% c.i
E Study or subgroup Edney <i>et al.</i> ²⁰ Fattah <i>et al.</i> ²¹ Phillips <i>et al.</i> ²⁵ Purcell <i>et al.</i> ²⁶ Rove <i>et al.</i> ²⁷ Short <i>et al.</i> ²⁸ Tan <i>et al.</i> ²⁹ Yalcin <i>et al.</i> ³¹ Total (95% c.i.) Total events Heterogeneity: $r^2 = 0.0$		AS Total 36 30 23 98 13 36 15 61 312 5.88, 6 d.1	<u>Corr</u> Events 10 1 5 9 7 10 0 9 51 51	trol Total 36 30 28 41 26 43 18 51 273 4; <i>J</i> ² = 09	Weight 4.6 1.8 12.9 36.2 4.7 16.0 23.9 100.0	(%) M-H (((((((((((((((((((Risk ratio 1, random, 95% c.i. 0.10 (0.01, 0.74) 0.33 (0.01, 7.87) 0.97 (0.30, 3.21) 0.84 (0.41, 1.71) 0.29 (0.04, 2.08) 0.48 (0.16, 1.40) Not estimable 0.74 (0.31, 1.79) 0.64 (0.42, 0.99) 0.01	Risk random	tio , 95% c.i.

Fig. 1 Forest plots: effectiveness of ERAS on all outcomes

a Length of hospital stay. b Time to oral intake. c Time to stool. d Rate of postoperative complications. e Rate of 30-day readmission. ERAS, enhanced recovery after surgery; MD, mean difference.

~
~
•

	ERAS Control MD							MD			
Study or subgroup	Mean	s.d.	Total	Mean	s.d.	Total	Weight (%)	IV, random, 95% c.i.	IV, random, 95% c.i.		
1.4.1 Adolescent											
Edney et al.20	2.67	0.74	36	4.67	2.96	36	8.8	-0.92 (-1.40, -0.43)	-		
Purcell et al.26	114.47	67.48	98	157.27	74.3	41	8.9	-0.61 (-0.98, -0.24)	•		
Short et al.28	3	1.48	36	4	1.48	43	8.8	-0.67 (-1.12, -0.21)	-		
Yalcin et al.31	1.92	0.64	61	2.54	0.66	51	8.9	-0.95 (-1.34, -0.56)	-		
Subtotal (95% c.i.)			231			171	35.3	-0.78 (-0.99, -0.57)	•		
Heterogeneity: $\tau^2 = 0.00$; $\chi^2 = 2.02$, 3 d.f., $P = 0.57$; $I^2 = 0\%$ Test for overall effect: $Z = 7.26$, $P < 0.00001$											
1.4.2 Child											
Fattah et al.21	1.93	2.23	30	4.23	2.96	36	8.7	-0.86 (-1.36, -0.35)			
Gao et al.22	4.81	0.28	68	7.74	0.26	57	7.0	-10.74 (-12.14, -9.34)			
Haid et al.23	11.93	0.64	15	19.87	2.04	15	6.7	-5.11 (-6.67, -3.55)			
Modrzyk et al.24	6.08	2.6	13	8.64	2.4	14	8.3	-0.99 (-1.80, -0.19)			
Phillips et al.25	155.8	84.7	28	235.8	195.2	23	8.7	-0.54 (-1.11, 0.02)	-		
Rove et al.27	5.7	5.1	13	8	7.3	26	8.5	-0.34 (-1.01, 0.33)	-		
Tan <i>et al.</i> ²⁹	5.3	0.6	15	9.1	2.5	18	8.2	–1.96 (–2.81, –1.11)			
Tlacuilo-Parra <i>et al.</i> ³⁰ Subtotal (95% c.i.)	13	5	30 212	72	40	30 219	8.6 64.7	-2.04(-2.67, -1.41) -2.71 (-4.19, -1.23)	▲		
Heterogeneity: $\tau^2 = 4.32$; $\chi^2 = 222.60$, 7 d.f., $P < 0.00001$; $I^2 = 97\%$ Test for overall effect: $Z = 3.59$, $P = 0.0003$											
Total (95% c.i.)			443			390	100.0	-1.94 (-2.73, -1.16)	•		
Heterogeneity: $\tau^2 = 1.77$; γ	$2^{2} = 241.0$	05, 11 c	I.f., P < 1	0.00001;	l ² = 95	%					
Test for overall effect: Z =	4.85, <i>P</i> =	= 0.000	01						-10 -5 0 5 10		
Test for subgroup differences: $\chi^2 = 6.44$, 1 d.f., $P = 0.01$; $l^2 = 84.5\%$ Favours ERAS Favours control											

-
-

		ERAS		(Contro	1		MD	MD
Study or subgroup	Mean	s.d.	Total	Mean	s.d.	Total	Weight (%) IV, random, 95% c.i	. IV, random, 95% c.i.
2.1.1 Adolescent									
Purcell et al.26	24.5	22.8	98	47.9	40.6	41	15.3	-0.80 (-1.18, -0.42)	-
Short et al.28	0.67	0.74	36	2	1.48	43	15.3	-1.10 (-1.57, -0.62)	•
Subtotal (95% c.i.)			134			84	30.6	-0.91 (-1.21, -0.62)	•
Heterogeneity: $\tau^2 = 0.00$; Test for overall effect: Z =	χ ² = 0.92, = 6.06, <i>P</i> <	1 d.f., : 0.000	<i>P</i> = 0.34 01	; <i>I</i> ² = 0%					
2.1.2 Child									
Fattah et al.21	1.23	0.68	30	2.9	1.45	30	15.1	-1.46 (-2.03, -0.88)	•
Gao et al.22	8.07	0.46	68	39.75	1.98	57	9.7	-22.84 (-25.74, -19.94)	
Modrzyk et al.24	3.23	1.8	13	6.14	2	14	14.7	-1.48 (-2.35, -0.61)	÷
Phillips et al.25	39	25	28	65.5	48.6	23	15.2	-0.70 (-1.27, -0.13)	
Tan et al.29	4.3	0.5	15	7.7	2	18	14.7	-2.18 (-3.07, -1.30)	
Subtotal (95% c.i.)			154			142	69.4	-5.07 (-7.73, -2.40)	\bullet
Heterogeneity: $\tau^2 = 8.78$; Test for overall effect: Z =	χ ² = 217.9 - 3.72, <i>P</i> =	97, 4 d. = 0.000	f., <i>P</i> < 0. 2	.00001; <i>I</i>	² = 98%	0			
Total (95% c.i.)			288			226	100.0	-3.37 (-4.84, -1.89)	◆ (
Heterogeneity: $\tau^2 = 3.65$;	$\chi^2 = 227.6$	60, 6 d.	f., <i>P</i> < 0.	00001; <i>I</i>	² = 97%	, 0			20 10 0 10 20
Test for overall effect: Z = Test for subgroup differer	= 4.48, <i>P</i> < nces: χ² =	: 0.000 9.20, 1	01 d.f., <i>P</i> =	= 0.002; <i>I</i>	² = 89.	1%			Favours ERAS Favours control

Fig. 2 Forest plots: subgroup analyses findings

a Length of hospital stay based on age group. b Time to oral intake based on age group. c Time to stool based on age group. d Time to stool based on surgery type. ERAS, enhanced recovery after surgery; MD, mean difference.

heterogeneity was present, a random-effects model was adopted. There were various methods used to explore the sources of heterogeneity. First, sensitivity analysis was used to maintain the pooled trials homogeneous by identifying and excluding the heterogeneous trials¹⁵. Second, subgroup analysis was carried out using predefined covariates¹⁵ age group (children or adolescent population) and type of surgery (urology, colorectal, or gastrointestinal). Publication bias was assessed using Begg and Mazumdar's test for rank correlation¹⁶ (Begg's test) and Egger's regression test¹⁷ (Egger's test) and visually inspected using a funnel plot (plotting inversed standard error against MD). A P value ≥0.05 for Begg's test and Egger's test for a regression indicated that there was no publication bias¹⁸. In addition, the Cook's distance was used to identify potential outliers by monitoring for patterns that consider both the leverage and residual of each trial¹⁹.

Results

The initial search generated 2371 records. A total of 277 duplicates were removed. Subsequently, 111 articles were retrieved for full-text review, of which 12 studies were included in this review. The PRISMA flowchart can be found in Fig. S1.

Study characteristics

A total of 827 patients were involved in the 12 studies^{20–31}, including two RCTs and 10 cohort studies, with sample sizes ranging from 30^{23} to 139^{26} . Table S2 shows the characteristics of all included studies. Ages ranged from 0.9 to 17 years. The specialties in the 12 included studies were colorectal (n=7), gastrointestinal (n=3), and urology (n=2). The number of ERAS elements implemented in each protocol ranged from 3 to 16

~		
_	^	÷

		ERAS			Contro	I		MD		MD)		
Study or subgroup	Mean	s.d.	Total	Mean	s.d.	Total	Weight (%) IV, random, 95% c.i.	1	V, random	, 95% c.	i.	
3.2.2 Adolescent													
Edney et al.20	14.07	10.67	36	38.83	32.59	36	17.5	-1.01 (-1.50, -0.52)			•		
Subtotal (95% c.i.)			36			36	17.5	-1.01 (-1.50, -0.52)			*		
Heterogeneity: Not applica	able												
Test for overall effect: Z =	4.02, P	< 0.000	01										
3.2.3 Child													
Fattah et al.21	1.43	0.86	30	1.83	1.02	30	17.5	-0.42 (-0.93, 0.09)					
Gao et al.22	17.18	0.94	68	44.39	1.82	57	14.4	–19.17 (–21.61, –16.73)					
Haid et al.23	11.93	0.64	15	19.87	2.04	15	16.2	-5.11 (-6.67, -3.55)					
Modrzyk et al.24	2.23	0.9	13	3.5	1.9	14	17.2	-0.82 (-1.61, -0.03)			•		
Rove et al.27	2	1.66	13	4	1.57	26	17.3	-1.22 (-1.95, -0.50)			•		
Subtotal (95% c.i.)			139			142	82.5	-5.05 (-8.12, -1.97)			·		
Heterogeneity: $\tau^2 = 11.80$;	$\chi^2 = 241$.73, 4 0	d.f., <i>P</i> <	0.00001;	$l^2 = 98$	%							
Test for overall effect: Z =	3.22, P	= 0.001											
Total (95% c.i.)			175			178	100.0	-4.19 (-6.37, -2.02)		•	·		
Heterogeneity: $\tau^2 = 6.98$; γ	² = 242.	83, 5 d.	f., <i>P</i> < 0	.00001; <i>I</i>	² = 98%	6		-					
Test for overall effect: Z =	3.78, P	= 0.000	2						-20	-10	0	10	20
Test for subgroup differen	ces: χ ² =	6.46, 1	d.f., P =	= 0.01; <i>1</i> ²	= 84.5	%			Fav	ours ERAS	Fa	vours co	ontrol



		ERAS			Contro			MD	MD
Study or subgroup	Mean	s.d.	Total	Mean	s.d.	Total	Weight (%)) IV, random, 95% c.i.	IV, random, 95% c.i.
3.1.1 Urology									
Haid et al.23	11.93	0.64	15	19.87	2.04	15	16.2	-5.11 (-6.67, -3.55)	
Rove et al.27	2	1.66	13	4	1.57	26	17.3	-1.22 (-1.95, -0.50)	+
Subtotal (95% c.i.)			28			41	33.4	-3.10 (-6.91, 0.70)	
Heterogeneity: $\tau^2 = 7.1$	6; $\chi^2 = 19$	9.58, 1	d.f., <i>P</i> <	0.00001	; <i>I</i> ² = 95	5%			
Test for overall effect:	Z = 1.60,	<i>P</i> = 0.1	1						
3.1.2 Colorectal									
Edney et al.20	14.07	10.67	36	38.83	32.59	36	17.5	-1.01 (-1.50, -0.52)	
Fattah et al.21	1.43	0.86	30	1.83	1.02	30	17.5	-0.42 (-0.93, 0.09)	•
Modrzyk et al.24	2.23	0.9	13	3.5	1.9	10	17.2	-0.82 (-1.61, -0.03)	-
Subtotal (95% c.i.)			79			80	52.1	-0.74 (-1.13, -0.36)	•
Heterogeneity: $\tau^2 = 0.0$	3; $\chi^2 = 2$.71, 2 d	.f., P = 0	.26; <i>I</i> ² =	26%				
Test for overall effect:	Z = 3.77,	P = 0.0	0002						
3.1.3 Gastrointestinal									
Gao et al.22	17.18	0.94	68	44.39	1.82	57	14.4 -	-19.17 (-21.61, -16.73)	
Subtotal (95% c.i.)			68			57	14.4 -	-19.17 (-21.61, -16.73)	◆
Heterogeneity: Not app	olicable								
Test for overall effect:	Z= 15.40), <i>P</i> < 0	.00001						
Total (95% c.i.)			175			178	100.0	-4.19 (-6.37, -2.02)	\bullet
Heterogeneity: $\tau^2 = 6.9$	8; χ ² = 24	42.83, 5	5 d.f., P	< 0.0000	1; /² = 9	98%		-	
Test for overall effect:	Z = 3.78,	P = 0.0	0002						-20 -10 0 10 20
Test for subgroup diffe	rences:)	ζ ² = 214	.74, 2 d	.f., <i>P</i> < 0.	00001;	$I^2 = 99.7$	1%		Favours Erras Favours control

Fig. 2 Continued

elements, with the most common being postoperative early oral intake and mobilization.

Methodological quality assessment

Critical appraisal of included studies is presented in *Table S3*. For the included RCTs, the nature of randomization and blinding was unclear. It was also unclear whether follow-up was completed in one study²¹. Among the cohort studies included, three^{23,24,29} did not identify confounding factors, and five^{23–25,28,29} did not address confounding factors. Question 8 was not applicable as outcomes appeared immediately after the intervention. Only two studies^{26,27} reported on follow-ups and explained the loss to follow-up.

LOS

All included studies reported LOS (Fig. 1a). Meta-analysis showed a considerable reduction in the LOS (MD -1.96; 95 per cent c.i. -2.75 to -1.17; Z=4.8, P<0.001), and considerable heterogeneity

 $(I^2 = 95 \text{ per cent})$. Sensitivity analysis was performed (Fig. S2a) and identified three heterogeneous studies^{22,23,30}, with I^2 decreased to 37 per cent and reporting a large effect size of -0.83 (95 per cent c.i. -1.05 to -0.60). The findings of Tlacuillo-Parra *et al.*³⁰ may be heterogeneous due to having only three ERAS elements as compared with the other studies that averaged 16 elements.

Subgroup analyses showed a statistically significant subgroup difference between different age groups (chi-squared 6.44, P = 0.010) (Fig. 2a), and that ERAS was effective in reducing LOS in adolescents with moderate effect (MD -0.78; 95 per cent c.i. -0.99 to -0.57; Z = 7.26, $P \le 0.001$). ERAS was more effective in children (2 to 12 years of age) in reducing LOS (MD -2.71; 95 per cent c.i. -4.19 to -1.23; Z = 3.59, P < 0.001). Subgroup differences among different types of surgery were statistically insignificant (Fig. S3a).

Time to oral intake

Eight studies involving 112 participants reported time to oral intake (Fig. 1b). One study was excluded from meta-analysis as



Fig. 3 Funnel plot: length of hospital stay

MD, mean difference.

they reported oral intake dichotomously³¹. Four studies^{21,24,28,29} reported time to oral intake in days, whereas three^{22,25,26} reported in hours. ERAS considerably reduces time to oral intake with a large effect size (MD –3.37; 95 per cent c.i. –4.84 to –1.89; Z = 4.48, P < 0.001).

Sensitivity analysis (Fig. S2b) was undertaken and one outlier²² was found. This study reported a 52 per cent increase in patients resuming oral intake on postoperative day 1 with the implementation of ERAS. Subgroup analyses of age groups and types of surgery were performed. Statistically significant subgroup difference (chi-squared 9.20, P=0.002) was found between age groups (Fig. 2b). Adolescents seem to experience smaller effect (MD –0.91; 95 per cent c.i. –1.21 to –0.62; Z=6.06, P<0.001) as compared with younger children (MD –5.07; 95 per cent c.i. –7.73 to –2.40; P<0.001). Subgroup differences for types of surgery was statistically insignificant (Fig. S3b).

Time to stool

Six studies involving 353 patients assessed the time to stool. Four^{21,23,24,27} reported time to stool in days and two^{20,22} reported it in hours. Meta-analyses revealed a considerable reduction in time to stool with a large effect size (MD -4.19; 95 per cent c.i. -6.37 to -2.02; Z = 3.78, P < 0.001) (Fig. 1c).

Sensitivity analysis detected one outlier²² (Fig. S2c). Subgroup analysis revealed significant differences (chi-squared 6.46, P=0.01) within age groups (Fig. 2c). In adolescents, ERAS implementation decreases time to stool with a large effect (MD -1.01; 95 per cent c.i. -1.50 to -0.52; Z=4.02, P<0.001) and an even larger effect was observed in children (MD -5.05; 95 per cent c.i. -8.12 to -1.97; Z=3.22, P=0.001). For types of surgery (Fig. 2d), subgroup analysis revealed significant differences in the reduction in time to stool and the three types of surgery (chi-squared 214.74, P<0.001). The effect of ERAS was statistically significant for colorectal and gastrointestinal surgery, with a moderate effect (MD -0.74; 95 per cent c.i. -1.13to -0.36; Z=3.77, P<0.001) and large effect (MD -19.17; 95 per cent c.i. -21.61 to -16.73; Z=15.40, P<0.001) respectively.

Rate of postoperative complications

Eight studies involving 571 patients were included in the meta-analysis of the rate of postoperative complications

(Fig. 1d). ERAS implementation resulted in a statistically significant (RR 0.50; 95 per cent c.i. 0.30 to 0.83; Z = 2.68, P = 0.007) reduction in the rate of postoperative complications by 50 per cent; with no heterogeneity. Subgroup analyses did not reveal any significant differences (Fig. S3c,d).

30-Day readmissions

Seven studies reported 30-day readmissions (Fig. 1e). ERAS resulted in statistically significant (RR 0.64; 95 per cent c.i. 0.42 to 0.99; Z = 2.02, P = 0.040) reduction in 30-day readmission by 36 per cent; with no heterogeneity. Subgroup analyses did not reveal any significant differences (Fig. S3e).

Publication bias

Publication bias was assessed for LOS using a funnel plot (Fig. 3). Examination of studentized residuals revealed that the study by Gao *et al.*²² was an outlier and overly influential according to Cook's distance, asserting the need for removal from the analysis. Both rank correlation (Z=-0.58, P=0.009) and the regression test (Z=-4.59, P=0.001) indicated potential funnel asymmetry, reinforcing the presence of publication bias.

Discussion

This systematic review and meta-analysis presented evidence of the effectiveness of ERAS in children undergoing abdominal surgery. It demonstrated a reduction in LOS of paediatric patients with a large effect, consistent with previous studies^{9,10} findings; however, the range of LOS reduction in this review (0.62-7.94 days) was less than other studies (1.3–13 days)⁹. The difference might be due to the types of surgical procedures performed, as the other review⁹ encompassed all types of paediatric surgery. Furthermore, most studies employed minimally invasive surgery such as laparoscopy, further reducing the LOS difference between ERAS and the control group. A reduction in LOS under ERAS implementation may further reduce hospitalization costs and allow better bed utilization³². The impact of ERAS in reducing LOS in younger children compared with adolescents may be related to the significant effects of ERAS in improving time to oral feeding and time to stool. Other underlying factors could be the inherent

physiological differences between adolescents and children, with adolescent physiology being similar to young adults³³.

The large effects observed with time to oral intake and time to stool may be associated with certain ERAS elements, which is consistent with findings from Arena *et al.*¹⁰. For example, early oral intake may reduce the risk of infection and anastomotic dehiscence³⁴. Furthermore, time to oral intake and stool are the most common discharge criteria for abdominal surgery³⁵. Similar to LOS findings, subgroup analyses saw a greater effect in children compared with adolescents for the time to oral intake, and time to stool; however, only time to stool revealed a significant difference following an analysis of the subgroup based on different types of surgery.

For other secondary outcomes, in contrast to that reported by Arena *et al.*¹⁰, this review demonstrated a 50 per cent reduction in the rate of postoperative complications and a 36 per cent reduction in the rate of 30-day readmission. Neither outcome showed significant subgroup differences based on age group and type of surgery. This could be due to a smaller number of studies and sample sizes included in the meta-analysis by Arena *et al.*¹⁰ which could result in a small study effect, thereby underestimating the true effect.

Larger sample size studies are needed in the future to determine the true effect of the ERAS protocol on the rate of postoperative complications and the rate of 30-day readmission; however, as most of the ERAS elements are already implemented in conventional care³⁶, it may be challenging to evaluate the effectiveness of ERAS protocols in paediatric settings as part of a quality improvement project.

In this review, the number of ERAS elements implemented in paediatric surgical settings has increased from 10⁹ to 16. ERAS guidelines/protocols were implemented as a bundle instead of single ERAS elements. In contrast, the comparator of three studies^{23,24,31} included single ERAS elements in conventional perioperative care; however, in the control group, there was low adherence to the implementation of these single elements. With the implementation of bundled ERAS protocols, there was an increase in adherence to these single ERAS elements. Implementing the ERAS protocol as a bundle could create a positive multiplicative effect on the clinical outcomes of LOS, time to oral intake, time to stool, postoperative complication rate, and 30-day readmission rate.

The results of this meta-analyses confirm the findings reported in past reviews about reducing LOS and improving other postoperative outcomes. Additionally, findings demonstrated that adherence to the implementation of ERAS elements as a bundle leads to improved postoperative outcomes. Institutions should provide structured guidelines and education to relevant staff members regarding the ERAS protocols to implement or promote adherence to the intervention.

Due to the high risk of bias in included studies, more robust evidence from well structured multicentre RCTs, or more rigorous observational studies, preferably with large sample sizes from multiple centres, is needed to further support and increase the generalisability of our review findings. Additionally, future research should explore the effects of ERAS on different paediatric surgical operations other than paediatric abdominal surgery. The authors propose that high-standard paediatric ERAS programme studies should provide well defined patient populations with specific eligibility criteria, ERAS protocol and assessment, an exclusive control group, clinically relevant outcomes, and measures of postoperative complications. In addition, strict adherence to the ERAS protocol and completeness of follow-up should be ensured. This study has limitations. First, the included studies had a small sample size, were mostly conducted in a single centre, and were mainly developed in the USA, thereby restricting the generalization of findings to other healthcare systems. Second, the broad age range and types of surgery might have caused substantial heterogeneity in our meta-analyses. Third, while intraoperative fluid management is a component of ERAS, the authors did not synthesize the results in this review as only the most commonly reported outcomes were selected. Last, all 10 cohort studies were of low quality with a high risk of bias due to their study design, which may have impacted the internal and external validity of this review.

The two RCTs were at high risk of selection and allocation bias because there was insufficient information provided to determine the randomization techniques and whether the blinding technique was carried out for participants and researchers. Ideally, the authors should have used the Cochrane risk of bias tool to assess the risk of bias of included trials; however, their team chose to use a common instrument (JBI critical appraisal instrument) that can cover all types of quantitative study designs. The JBI has developed many critical appraisal checklists involving the feasibility, appropriateness, meaningfulness, and effectiveness of healthcare interventions³⁷.

Funding

The publication of this review was funded by the Department of Paediatric Surgery, National University Hospital, Singapore.

Acknowledgements

The authors appreciate the great support from the librarian for the assistance in working out the search terms for this review. B.A.H. and Z.A. contributed equally to the manuscript. The review protocol was not preregistered in any independent, institutional registry; however, it was finalized and submitted to the authors' institution on 11 December 2020 and is available upon request.

Disclosure

The authors declare no conflict of interest.

Supplementary material

Supplementary material is available at BJS Open online.

Data availability

Template data collection forms; data extracted from included studies; data used for all analyses; analytic code; and any other materials used in the review are available on request from the corresponding author.

References

- Sømme S, Bronsert M, Morrato E, Ziegler M. Frequency and variety of inpatient paediatric surgical procedures in the United States. *Paediatrics* 2013;**132**:e1466–e1472
- Kehlet H. Multimodal approach to control postoperative pathophysiology and rehabilitation. Br J Anaesth 1997;78:606–617

- 3. ERAS Society. Enhanced Recovery After Surgery. https:// erassociety.org/ (accessed 23 August 2022)
- Senturk JC, Kristo G, Gold J, Bleday R, Whang E. The development of enhanced recovery after surgery across surgical specialties. J Laparoendosc Adv Surg Tech A 2017;27:863–870
- Puett LL, Smith L. Feasibility of enhanced recovery protocols in children. J Pediatr Surg Nurs 2018;7:9–19
- Raval MV, Dillon PW, Bruny JL, Ko CY, Hall BL, Moss RL et al. Paediatric American College of Surgeons national surgical quality improvement program: feasibility of a novel, prospective assessment of surgical outcomes. J Pediatr Surg 2011;46:115–121
- Steinman MA, Fischer MA, Shlipak MG, Bosworth HB, Oddone EZ, Hoffman BB et al. Clinician awareness of adherence to hypertension guidelines. Am J Med 2004;117:747–754
- Lau CS, Chamberlain RS. Enhanced recovery after surgery programs improve patient outcomes and recovery: a meta-analysis. World J Surg 2017;41:899–913
- Shinnick JK, Short HL, Heiss KF, Santore MT, Blakely ML, Raval MV. Enhancing recovery in paediatric surgery: a review of the literature. J Surg Res 2016;202:165–176
- Arena S, Di Fabrizio D, Impellizzeri P, Gandullia P, Mattioli G, Romeo C. Enhanced recovery after gastrointestinal surgery (ERAS) in paediatric patients: a systematic review and meta-analysis. J Gastrointest Surg 2021;25:2976–2988
- 11. Page MJ, Higgins JP, Sterne JA. Assessing risk of bias due to missing results in a synthesis. In: Cochrane Handbook for Systematic Reviews of Interventions. Cochrane Collaboration. Chichester: John Wiley & Sons, 2019, 349–374
- Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009;6:e1000097
- Tufanaru C, Munn Z, Aromataris E, Campbell J, Hopp L. Systematic reviews of effectiveness. In: Aromataris E, Munn Z (eds), JBI Manual for Evidence Synthesis. Chichester: John Wiley & Sons, 2020. https://synthesismanual.jbi.global
- Moola S, Munn Z, Tufanaru C, Aromataris E, Sears K, Sfetc R et al. Systematic reviews of etiology and risk. In: Aromataris E, Munn Z (eds), JBI Manual for Evidence Synthesis. Chichester: John Wiley & Sons, 2020. doi:10.46658/JBIMES-20-04
- Deeks JJ, Higgins JP, Altman DG; Group obotCSM. Analysing data and undertaking meta-analyses. In: Cochrane Handbook for Systematic Reviews of Interventions. Cochrane Collaboration, Chichester: John Wiley & Sons, 2019, 241–284
- Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994;50:1088–1101
- 17. Egger M, Smith GD, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;**315**:629–634
- Lin L, Chu H. Quantifying publication bias in meta-analysis. Biometrics 2018;74:785–794
- Cook RD, Weisberg S. Residuals and Influence in Regression. New York: Chapman & Hall, 1982
- 20. Edney JC, Lam H, Raval MV, Heiss KF, Austin TM. Implementation of an enhanced recovery program in paediatric laparoscopic colorectal patients does not worsen analgesia despite reduced perioperative opioids: a retrospective, matched, non-inferiority study. *Reg Anesth Pain Med* 2019;**44**:123–129
- 21. Abdel Fattah ARA, El-Rouby AAM. Improving the outcome of paediatric emergency abdominal surgeries by application of enhanced recovery after surgery protocol. *Res Opin Anesth Intensive Care* 2020;**7**:91

- Gao R, Yang H, Li Y, Meng L, Li Y, Sun B et al. Enhanced recovery after surgery in paediatric gastrointestinal surgery. J Int Med Res 2019;47:4815–4826
- Haid B, Karl A, Koen M, Mottl W, Haid A, Oswald J. Enhanced recovery after surgery protocol for paediatric urological augmentation and diversion surgery using small bowel. J Urol 2018;200:1100–1106
- Modrzyk A, Pasierbek MJ, Korlacki W, Grabowski A. Introducing enhanced recovery after surgery protocol in paediatric surgery. *Adv Clin Exp Med* 2020;29:937–942
- Phillips MR, Adamson WT, McLean SE, Hance L, Lupa MC, Pittenger SL et al. Implementation of a paediatric enhanced recovery pathway decreases opioid utilization and shortens time to full feeding. J Pediatr Surg 2020;55:101–105
- Purcell LN, Marulanda K, Egberg M, Mangat S, McCauley C, Chaumont N et al. An enhanced recovery after surgery pathway in paediatric colorectal surgery improves patient outcomes. J Pediatr Surg 2021;56:115–120
- Rove KO, Brockel MA, Saltzman AF, Dönmez MI, Brodie KE, Chalmers DJ et al. Prospective study of enhanced recovery after surgery protocol in children undergoing reconstructive operations. J Pediatr Urol 2018;14:252.e1–252.e9
- Short HL, Heiss KF, Burch K, Travers C, Edney J, Venable C et al. Implementation of an enhanced recovery protocol in paediatric colorectal surgery. J Pediatr Surg 2018;53:688–692
- Tan Y, Shen Y, Li L, Yu J. Protocol for enhanced recovery after surgery with 3D laparoscopic excision for choledochal cysts can benefit the recovery process. *Pediatr Surg Int* 2020;36: 643–648
- 30. Tlacuilo-Parra A, López-Valenzuela S, Ambriz-González G, Guevara-Gutiérrez E. Safety and effectiveness of the fast-track attention model vs. conventional care in uncomplicated appendicitis of the paediatric patient [seguridad y eficacia del modelo de atención fast-track vs. Atención convencional en apendicitis no complicada del paciente pediátrico]. Cir Cir 2018;**86**:412–416
- Yalcin S, Walsh SM, Figueroa J, Heiss KF, Wulkan ML. Does ERAS impact outcomes of laparoscopic sleeve gastrectomy in adolescents? Surg Obes Relat Dis 2020;16:1920–1926
- Rojas-García A, Turner S, Pizzo E, Hudson E, Thomas J, Raine R. Impact and experiences of delayed discharge: a mixed-studies systematic review. *Health Expect* 2018;21:41–56
- Leeds IL, Boss EF, George JA, Strockbine V, Wick EC, Jelin EB. Preparing enhanced recovery after surgery for implementation in paediatric populations. J Pediatr Surg 2016;51:2126–2129
- Lewis SJ, Egger M, Sylvester PA, Thomas S. Early enteral feeding versus "nil by mouth" after gastrointestinal surgery: systematic review and meta-analysis of controlled trials. *BMJ* 2001;**323**: 773–776
- Fiore JF, Browning L, Bialocerkowski A, Gruen RL, Faragher IG, Denehy L. Hospital discharge criteria following colorectal surgery: a systematic review. Colorectal Dis 2012;14:270–281
- Brindle ME, Heiss K, Scott MJ, Herndon CA, Ljungqvist O, Koyle MA. Embracing change: the era for paediatric ERAS is here. *Pediatr Surg Int* 2019;35:631–634
- 37. Ma L-L, Wang Y-Y, Yang Z-H, Huang D, Weng H, Zeng X-T. Methodological quality (risk of bias) assessment tools for primary and secondary medical studies: what are they and which is better? Mil Med Res 2020;7:7